Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity
Stopped The enrollment rate at most centers was unlikely to result in the recruitment of the planned sample size of 40 evaluable subjects.
Conditions
- Multiple Sclerosis
- Overactive Detrusor
Interventions
- DRUG: Darifenacin (BAY79-4998)
Sponsor
Bayer